These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 2066388)
1. [The effect of extract from human tubercle bacilli (SSM) on HBeAg positive type B chronic hepatitis]. Fujisaki S; Satomura K; Aramaki T; Okumura H Nihon Ika Daigaku Zasshi; 1991 Apr; 58(2):165-72. PubMed ID: 2066388 [TBL] [Abstract][Full Text] [Related]
2. Effects of SSM (specific substance maruyama) on HBe antigen-positive chronic hepatitis B -clinical efficacy and modulation of cytokines. Satomura K; Yin M; Sekiyama T; Fujisaki S; Aramaki T; Okumura H; Ohmoto Y J Nippon Med Sch; 2000 Aug; 67(4):261-6. PubMed ID: 10938594 [TBL] [Abstract][Full Text] [Related]
3. Cianidanol therapy for HBe-antigen-positive chronic hepatitis: a multicentre, double-blind study. Suzuki H; Yamamoto S; Hirayama C; Takino T; Fujisawa K; Oda T Liver; 1986 Feb; 6(1):35-44. PubMed ID: 3520204 [TBL] [Abstract][Full Text] [Related]
4. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Fattovich G; Rugge M; Brollo L; Pontisso P; Noventa F; Guido M; Alberti A; Realdi G Hepatology; 1986; 6(2):167-72. PubMed ID: 3957228 [TBL] [Abstract][Full Text] [Related]
5. Preference and significance of HBeAg and anti-HBe, determined by enzyme immunoassay, in patients with acute, chronic and resolved hepatitis B. Niermeijer P; Gips CH; Huizenga JR; van der Waart M; Schuurs A Hepatogastroenterology; 1980 Oct; 27(5):350-5. PubMed ID: 7203369 [TBL] [Abstract][Full Text] [Related]
6. Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. Loriot MA; Marcellin P; Bismuth E; Martinot-Peignoux M; Boyer N; Degott C; Erlinger S; Benhamou JP Hepatology; 1992 Jan; 15(1):32-6. PubMed ID: 1727796 [TBL] [Abstract][Full Text] [Related]
7. HBeAg/anti-HBe antigenic system in liver diseases in Greece. Theodoropoulos G; Nakopoulou L; Fertakis A; Papaevangelou G; Hadzis G; Kasfiki A Hepatogastroenterology; 1983 Dec; 30(6):243-5. PubMed ID: 6327477 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of a new radioimmunoassay for detecting hepatitis B e antigen and its antibody. Löfgren B; Nordenfelt E J Med Virol; 1980; 5(4):323-30. PubMed ID: 7229621 [TBL] [Abstract][Full Text] [Related]
9. IgG subclasses in circulating immune complexes with hepatitis B e antigen in chronic hepatitis B. Sällberg M; Norder H; Lindh G; Magnius LO Clin Exp Immunol; 1991 Apr; 84(1):116-21. PubMed ID: 2015701 [TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of HBeAg and anti-HBe in HBsAg positive liver diseases]. Takahashi A; Sekiya C; Yazaki Y; Tominaga Y; Oohara K; Ono M; Sato H; Hasebe C; Namiki M Hokkaido Igaku Zasshi; 1983 Jan; 58(1):30-42. PubMed ID: 6840666 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of HBeAg and HBsAg seroconversion in patients with chronic hepatitis B. Stránský J; Chlumská A; Zichová M; Helm R; Mankovecký L; König J Sb Lek; 1993; 94(4):317-25. PubMed ID: 7992018 [TBL] [Abstract][Full Text] [Related]
12. High frequency of hepatitis B virus DNA in anti-HBe positive sera on longitudinal follow-up of patients with renal transplants and chronic hepatitis B. Norder H; Brattström C; Magnius L J Med Virol; 1989 Apr; 27(4):322-8. PubMed ID: 2656911 [TBL] [Abstract][Full Text] [Related]
13. Incidences of HBeAg and anti-HBe in, and clinical course of hepatitis B virus carriers. Tsuchie H; Kurimura O; Tamura I; Shimase K; Kaneto E; Kurimura T; Tsuda F; Mayumi M Biken J; 1984 Dec; 27(4):169-76. PubMed ID: 6100353 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis Be antigen and antibody in chronic liver diseases and hepatocellular carcinoma. Chen DS; Sung JL; Lai MY Hepatogastroenterology; 1981 Dec; 28(6):288-91. PubMed ID: 6284625 [TBL] [Abstract][Full Text] [Related]
15. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. Krogsgaard K; Marcellin P; Trepo C; Berthelot P; Sanchez-Tapias JM; Bassendine M; Tran A; Ouzan D; Ring-Larsen H; Lindberg J; Enriquez J; Benhamou JP; Bindslev N J Hepatol; 1996 Dec; 25(6):803-13. PubMed ID: 9007706 [TBL] [Abstract][Full Text] [Related]
16. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Liaw YF; Tai DI; Chu CM; Pao CC; Chen TJ Hepatology; 1987; 7(1):20-3. PubMed ID: 2433203 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus DNA in asymptomatic HBsAg carriers: comparison with HBeAg/anti-HBe status. Berris B; Sampliner RE; Sooknanan R; Feinman SV J Med Virol; 1987 Nov; 23(3):233-9. PubMed ID: 3430143 [TBL] [Abstract][Full Text] [Related]
18. HBeAg seroconversion in children infected during early childhood with hepatitis B virus. Roushan MR; Bijani A; Ramzaninejad S; Roushan MH; Amiri MJ; Baiani M J Clin Virol; 2012 Sep; 55(1):30-3. PubMed ID: 22727680 [TBL] [Abstract][Full Text] [Related]
19. The HBe antigen-antibody system and its relationship to clinical and laboratory findings in 100 chronic HBsAg carriers in Great Britain. Viola LA; Barrison IG; Coleman JC; Paradinas FJ; Murray-Lyon IM J Med Virol; 1981; 8(3):169-75. PubMed ID: 7328422 [TBL] [Abstract][Full Text] [Related]
20. Evolution of HBeAg/anti-HBe status and its relationship to clinical and histological outcome in chronic HBV carriers in childhood. Sodeyama T; Kiyosawa K; Akahane Y; Tanaka E; Wada S; Oike Y; Nakamura M; Yoda H; Imai Y; Gibo Y Am J Gastroenterol; 1986 Apr; 81(4):239-45. PubMed ID: 3962948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]